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Cardiomyopathies are a diverse group of diseases affecting the heart muscle1; many of them are inherited and transmit-
ted in autosomal dominant patterns. The first cardiomyopathy 
genes were identified by genome-wide linkage analysis in large 
families.2 In practice, however, the small size of most families, or 
even the availability of members of larger families, often limits 
the power of linkage analysis. Recently, high throughput next-
generation sequencing techniques have become widely acces-
sible, making whole genome sequencing (WGS) cost-effective 
and time-effective. However, the abundance of variation in the 
human genome3 makes it difficult to distinguish rare benign 
variants from rare disease-causing mutations in an isolated 
individual, even with growing knowledge of variants in popu-
lation cohorts (eg, >60 000 sequenced exomes in the Exome 
Aggregation Consortium (ExAC) database, http://exac.broadin-
stitute.org/). Next-generation sequencing poses, therefore, a 
significant clinical challenge: the capability to assess variants 
Background—High throughput next-generation sequencing techniques have made whole genome sequencing accessible in 
clinical practice; however, the abundance of variation in the human genomes makes the identification of a disease-causing 
mutation on a background of benign rare variants challenging.
Methods and Results—Here we combine whole genome sequencing with linkage analysis in a 3-generation family affected 
by cardiomyopathy with features of autosomal dominant left ventricular noncompaction cardiomyopathy. A missense 
mutation in the giant protein titin is the only plausible disease-causing variant that segregates with disease among the 
7 surviving affected individuals, with interrogation of the entire genome excluding other potential causes. This A178D 
missense mutation, affecting a conserved residue in the second immunoglobulin-like domain of titin, was introduced 
in a bacterially expressed recombinant protein fragment and biophysically characterized in comparison to its wild-type 
counterpart. Multiple experiments, including size exclusion chromatography, small-angle x ray scattering, and circular 
dichroism spectroscopy suggest partial unfolding and domain destabilization in the presence of the mutation. Moreover, 
binding experiments in mammalian cells show that the mutation markedly impairs binding to the titin ligand telethonin.
Conclusions—Here we present genetic and functional evidence implicating the novel A178D missense mutation in titin as 
the cause of a highly penetrant familial cardiomyopathy with features of left ventricular noncompaction. This expands 
the spectrum of titin’s roles in cardiomyopathies. It furthermore highlights that rare titin missense variants, currently 
often ignored or left uninterpreted, should be considered to be relevant for cardiomyopathies and can be identified by the 
approach presented here.  (Circ Cardiovasc Genet. 2016;9:426-435. DOI: 10.1161/CIRCGENETICS.116.001431.)
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as pathogenic lags significantly behind variant identification, 
especially for nonsynonymous point mutations.4,5 Algorithmic 
predictors are currently unable to accurately assess their exact 
impact on protein–protein interactions or even on protein fold-
ing. Experimental validation of genetic variants is, therefore, 
an increasingly indispensable component of next-generation 
sequencing discoveries.
In the current study, we combine WGS with linkage analysis 
in a medium-sized family affected by cardiomyopathy, with fea-
tures of left ventricular noncompaction cardiomyopathy (LVNC). 
By performing WGS in 2 family members, filtering against vari-
ants seen in normal population cohorts and using linkage informa-
tion derived from single nucleotide polymorphism (SNP) arrays 
of 13 family members, we could identify a missense variant in 
the titin gene (TTN) as the most plausible cause of disease in the 
family. Functional data generated from biophysical and protein-
binding experiments on this titin missense variant provide further 
support of a causative role in cardiomyopathy through domain 
misfolding and destabilization, resulting in impaired binding 
to the ligand telethonin (also known as t-cap).
Methods
Clinical Evaluation
The study was approved by the Oxfordshire Research Ethics 
Committee B (REC Ref 09/H0605/3), and all subjects gave informed 
consent. A 3-generational family with history of cardiomyopathy was 
recruited. Clinical assessment and genetic studies were performed 
in available family members, who had clinical examination, ECG, 
echocardiography (with contrast agent where appropriate), and car-
diac magnetic resonance imaging, if possible. Diagnosis of cardio-
myopathy was based on established criteria. The diagnosis of LVNC 
was based on published criteria from echocardiographic or cardiac 
magnetic resonance imaging6,7: the compaction ratio, that is, the ratio 
of the thickness of noncompacted to compacted myocardium >2.3 
measured on magnetic resonance imaging in diastole or >2.0 on 
echocardiography in systole, was used to diagnose LVNC.
Genetic Studies
SNP array genotyping was performed using the Illumina 
HumanCytoSNP-12v1 BeadChip (Illumina, San Diego, CA), contain-
ing nearly 300 000 genetic markers, according to the manufacturer’s 
protocols. A refined subset of roughly 24 000 SNPs in approximate 
linkage equilibrium was generated using the software PLINK v1.078 
and the HapMap genotype file available from the PLINK website 
(http://pngu.mgh.harvard.edu/purcell/plink/). Linkage analysis of 
the SNP subset was performed using MERLIN v1.1.2,9 specifying 
an autosomal dominant disease model. Genomic intervals with loga-
rithm of the odds scores >0, compatible with segregation of variants 
in these regions, were selected for downstream analyses.
WGS was performed on genomic DNA extracted from peripheral 
blood as part of the WGS500 project as described previously.10
Sequence reads from the affected individuals were mapped to 
the human reference genome (hs37d5 version of build 37) using 
STAMPY.11 Duplicate reads were removed with PICARD (http://
broadinstitute.github.io/picard/). The software Platypus (version 
0.8.1, default parameters)12 was used jointly on the two.bam files to 
call SNPs and short (<50 bp) indels across both samples.
All the 5 946 161 identified variants were annotated with an in-
house pipeline based on the Variant Effect Predictor Ensembl frame-
work (version 77).13 Several additional databases were used to integrate 
the information provided by Variant Effect Predictor (Table I in the 
Data Supplement). Known associations with diseases were screened 
using HGMD (http://www.hgmd.cf.ac.uk/ac/index.php) and ClinVar.14
Variants were filtered by in-house Python scripts based on criteria 
outlined in Table I in the Data Supplement (steps 1–10), followed by 
manual inspection (steps 11–13). The variants remaining after step 
10 are documented in Results and in Tables II and III in the Data 
Supplement. Confirmatory Sanger sequencing was performed with 
the primers listed in Table IV in the Data Supplement.
Both SNP and WGS data were interrogated also for clinically 
relevant copy number variants using Nexus Copy Number 7.5.2 
Discovery Edition (BioDiscovery, Hawthorne, CA; see Methods in 
the Data Supplement).
Functional Characterization of the Titin Missense 
Variant
The mutation was introduced into human titin Z1Z2 constructs (amino 
acids 1–196, accession no ACN81321.1) for bacterial and mammalian 
expression using Quikchange II XL (Agilent) with primers given in 
Table IV in the Data Supplement. Bacterial expression and purification 
was performed as previously described.15 Size exclusion chromatogra-
phy–Tridetector analysis (light scattering, refractive index, and UV ab-
sorbance), small-angle x ray scattering experiments, circular dichroism 
spectroscopy, and thermolysin digests were essentially performed as de-
scribed,15–18 and experimental details are given in the Data Supplement.
Neonatal rat cardiomyocyte (NRC) cultures were established and 
transfected16 using hemagglutinin-tagged expression constructs and 
counterstained for titin T12 epitope19 or telethonin (mouse monoclo-
nal antibody, Santa Cruz) 48 hours post transfection and analyzed by 
confocal microscopy.
Glutathione S-transferase (GST) pulldown assays were performed 
as described20 using mammalian expression constructs for telethonin 
amino acids 1 to 90 and 1 to 167 fused to GST and titin Z1Z2 fused 
to GFP (pEGFP-N1, Clontech) in transfected COS-1 cells. Förster 
Resonance Energy Transfer experiments from transfected COS-
1 cells and the assessment of reduced protein stability in NRC and 
COS-1 cells are described in the Data Supplement.
Results
The proband was a 20-year-old male (II-3 in Figure 1A) who 
died suddenly in hospital in 1970 having presented with rap-
idly decompensating congestive heart failure; at postmortem, 
his heart (680 g) had evidence of dilatation and both macro-
scopic and microscopic hypertrophy but no myocyte disarray. 
His brother (II-4) was later found to have an enlarged heart 
with wall thickness at the upper limit of normal and marked 
hypertrabeculation. The proband’s sister (II-2) presented with 
a non–ST-segment–elevation myocardial infarct because of 
coronary embolus at the age of 61 years. LVNC with mild left 
ventricular dilatation and apical hypertrophy was diagnosed 
at this time (Figure 1B and 1C). Cascade screening identified 
the same condition in further family members with consistent 
clinical features of adult onset cardiomyopathy with features 
of LVNC. Five affected family members had sufficient non-
compaction to meet the diagnostic criteria for LVNC, while 3 
others with early or mild disease had lesser extent of hyper-
trabeculation but clear evidence of cardiomyopathy with left 
ventricular dilatation or systolic dysfunction (Figure 1A and 
Table 1; Figure I in the Data Supplement). Aside from the 
proband who had advanced congestive failure, there were no 
arrhythmic features in any affected family member, nor were 
there any extracardiac (eg, neuromuscular) manifestations.
Identification of TTN Mutation A178D Segregating 
With Disease
Affected first cousins III-1 and III-4 were selected for WGS. 
Sequencing was performed by Illumina Cambridge as 100-
bp paired-end reads to a mean coverage of 56.9× and 52.0×, 
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Figure 1. A, Pedigree of the family; males depicted as squares; females, circles; slanted symbols, deceased individuals. Clinically 
affected individuals are marked in gray, unaffected are shown in white, and ? means unclassified clinical status. The presence of the TTN 
p.A178D mutation is indicated (+ indicates present; −, absent; ND, not determined.) Individuals selected for whole genome sequencing 
(WGS) are marked with thicker symbols (III-1 and III-4). B, Echocardiogram images showing the characteristic spongy appearance of non-
compaction in individual II-2 with and without contrast. C, Echocardiogram image from individual II-4 showing significant dilatation, but 
maintaining a thickened myocardium and preserved ejection fraction.
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respectively, such that 99% of the genome was covered at 20× or 
more in both samples, identifying 5 946 161 variants shared by the 2 
individuals. In addition, SNP arrays were performed on all individu-
als of the family (except II-3 and III-2; Figure 1A). Neither the SNP 
array nor WGS data revealed likely causative copy number variants.
Genomic regions identical by descent were identified 
through linkage analysis (see Methods and Figure II in the Data 
Supplement), and out of the 100 789 candidate variants within the 3 
linkage regions (on chromosomes 2, 9, and 16), potentially patho-
genic ones were selected based on an autosomal dominant model, 
Table 1.  Summary of Clinical Findings
Symbol Sex Age*
Clinical 
Status†
Genetic 
Status
Trabeculation 
Compaction 
Ratio (CR)‡ IVSD PWD LVEDD LVESD EF ECG Comments
I-1 M 87 Affected TTN A178D 2.5 (echo) 24 13 40 35 42 Left axis 
deviation, 
anteroseptal 
Q wave
Marked ASH with  
low EF, CVA, hypertension; 
meets diagnostic criteria  
for LVNC (echo)
I-2 F 72 Unaffected WT 1.8 (echo) 12 11 48 30 76 AF, paced LVNC excluded (echo), 
structurally normal heart 
at age 70 y, moderate 
concentric LVH by age 85 y
II-2 F 61 Affected TTN A178D 2.0 (echo) 9 10 53 36 47 Left axis 
deviation
Mildly thickened apical 
segments, cardiac embolus 
at 61 y; meets diagnostic 
criteria for LVNC (echo)
II-3 M 20 Assumed 
affected
No DNA        Rapidly progressive HF with 
sudden death at 20 y (1970); 
hypertrophy and dilatation at 
postmortem
II-4 M 37 Affected TTN A178D <2 (MRI) 12 12 64 44 57 Normal Dilated LV, late Gd on MRI, 
hypertension
II-6 M 42 Unaffected WT  11 9 50 30 78 Normal  
III-1 M 27 Affected TTN A178D 2.5 (echo) 12 11 64 42 63 QRS 120 ms Mild regional systolic 
dysfunction; meets 
diagnostic criteria for  
LVNC (echo)
III-2 M 21 Unclassified No DNA 0.8 (echo) 13 13 54 37 68 Normal Mild concentric LVH
III-3 M 32 Affected TTN A178D 2.8 (MRI) 11 13 52 35 68 Normal Hypertension;  
meets diagnostic criteria  
for LVNC (MRI)
III-4 F 23 Affected TTN A178D 2.6 (MRI) 8 9 46 32 58 Normal Meets diagnostic  
criteria for LVNC (MRI)
III-5 M 25 Affected TTN A178D 2.0–2.5 (MRI) 10 10 46 27 51 Inferior 
T-wave 
inversion
Hypokinesia apical  
LV incl. septum; borderline 
for diagnostic criteria for 
LVNC (MRI)
III-6 M 23 Affected TTN A178D 1.5 (MRI) 8 9 53 34 48 Q wave and 
T-wave 
inversion in 
lead III
Mild DCM, faint late Gd, 
borderline dilated LV with 
mildly impaired function, 
inferior hypokinesia
III-7 M 21 Unclassified WT 1.6 (MRI) 9 7 55 38 59 Normal Documented myocarditis  
at 21 y (MRI)
Cardiac dimensions are given in mm. Blank cells indicate no data available. AF indicates atrial fibrillation; ASH, asymmetrical septal hypertrophy; CVA, cerebrovascular 
accident; DCM, dilated cardiomyopathy; EF, ejection fraction (in %); Gd, gadolinium; HF, heart failure; IVSD, interventricular septal thickness at diastole; LVEDD, left 
ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVH, left ventricular hypertrophy; LVNC, left ventricular noncompaction cardiomyopathy; 
MRI, magnetic resonance imaging; PWD, posterior wall thickness at diastole; and TTN, titin.
*Age of diagnosis or first clinical assessment; however, parameters of most recent cardiac assessment are given (with exception of I-2, where data at first assessment 
aged 70 y are given, and II-7, where the last assessment before myocarditis is shown).
†Clinical status affected means affected by cardiomyopathy. Whether individuals meet diagnostic criteria for LVNC is shown in the Comments column (whether MRI 
or echo criteria have been used is shown in brackets).
‡For the definition of trabeculation compaction ratio (CR), see Methods section; the mode of imaging is indicated in brackets. Representative MRI images are shown 
in Figure I in the Data Supplement.
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caused by a rare heterozygous mutation. Variants were filtered 
accordingly by in-house Python scripts, and the remaining 6 vari-
ants were manually inspected (Table II in the Data Supplement). 
Four of them were excluded: one is assumed to be an artifact 
because of an incorrect transcript being present in Ensembl and 
another variant did not segregate with disease in the family; 2 splice 
variants were predicted to be silent (at positions -5 and -3 of a 3′ 
splice junction, respectively; for details, see Table III in the Data 
Supplement). Only 2 final candidate variants were considered con-
ceivably linked to the phenotype: missense changes in PDP2 and 
TTN, respectively (Table II in the Data Supplement). PDP2 codes 
for pyruvate dehyrogenase phosphatase catalytic subunit 2 and has 
low expression levels in the heart. Although the change E316K is 
predicted to be damaging by Polyphen and SIFT algorithms (Table 
II in the Data Supplement), a heterozygous loss-of-function in 
this enzyme would not be expected to produce a phenotype, and 
indeed, heterozygous loss-of-function mutations in PDP1 are clini-
cally silent.21 The variant is not plausible as a cause of a penetrant-
dominant disorder because it is found 6× in 121 412 alleles in the 
ExAC database. Six instances would equal at least 10% of all 
expected LVNC cases in ExAC, assuming a maximal prevalence 
of 1:1000 for the disease.22 This seems to be an implausibly high 
percentage for a novel, unpublished disease-causing variant. In 
support, in the 2 largest clinical cardiomyopathy cohorts published 
to date, the most common reported pathogenic variant (MYBPC3, 
p.Arg502Trp) detected in 104 out of 6179 hypertrophic cardio-
myopathy cases (1.7%, 95% confidence interval 1.4%–2.0%) 
was only observed 3× in ExAC (3/120 674), with all other patho-
genic variants for hypertrophic cardiomyopathy or dilated cardio-
myopathy (DCM) being present 0 or 1 time only.23
The second variant is found in TTN, the gene that codes for 
titin, an abundant skeletal muscle and heart-specific protein with 
crucial functions24,25 (and reviewed in Gerull26 et al). Mutations 
in titin have been associated with cardiomyopathy and skeletal 
myopathy (reviewed in Chauveau et al27). The identified missense 
variant c.533C>A in TTN, which codes for a p.A178D change 
at the amino acid level, is absent in ExAC. Sanger sequencing 
confirmed the cosegregation of the heterozygous mutation with 
disease in all affected individuals of the family (Figure 1; Figure 
IIIA in the Data Supplement; logarithm of the odds score 2.1). 
Thus, comprehensive whole genome analysis reveals this as the 
most plausible causative mutation in the family.
Functional Studies
Prediction of Deleterious Effects of the Mutation
Each single molecule of the giant protein titin spans half a sarco-
mere from the Z disk to the M band.28 The first 2 immunoglob-
ulin-like domains (Z1Z2) of titin are located in the Z disk and 
form a superstable complex with telethonin.29 The A178 position 
is evolutionarily well conserved back to zebrafish and lamprey. 
Additionally, A178 is located in a highly conserved structural 
section (Figure IIIB in the Data Supplement), the β-strand F of 
the second immunoglobulin domain of Z1Z2, neighboring the 
β-strand G of titin Z2, which forms a strong and extended inter-
action with the β-strands of telethonin30 (Figure 2A). The A178D 
mutation is predicted to directly affect the β-strands B and C and 
the loop connecting the β-strands B and C because of steric hin-
drance of D178 with V127 and P133, respectively (Figure 2B). 
Thus, the insertion of a charged residue in this position is likely to 
have significant impact on the secondary structure of this domain 
and could potentially cause misfolding of the protein.
Altered Protein Characteristics of Purified Titin Z1Z2 
A178D Recombinant Fragment
To assess how the A178D mutation affects the folding and stabil-
ity of the protein, recombinant titin Z1Z2 WT and A178D were 
Figure 2. A, Position of the TTN p. A178D on a structural model (pdb: 1YA5) of the titin Z1Z2 domains (purple) in complex with telethonin 
(pink). B, Close-up of the site of mutation. The red discs show van der Waals overlaps or steric clashing that A178D is predicted to cause 
with valine127 and proline133. The figures of the crystal structure were generated by Pymol (http://www.pymol.org).
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expressed in Escherichia coli and purified under native conditions. 
Of note, the yield of the soluble protein fraction was consistently 
lower for A178D compared with WT preparations, despite equal 
total expression levels (data not shown). Circular dichroism spec-
troscopy demonstrated a typical β-sheet signature for WT Z1Z2 
(Figure 3A). In contrast, the spectrum for Z1Z2 A178D differs 
significantly: although the characteristic negative band at 216 nm 
is still present, but slightly shifted, there was no significant posi-
tive band at around 200 nm. The absence of this band, associated 
with β-sheet conformation, and the presence of a negative peak at 
around 198 nm, characteristic of random coil structures, indicate 
that the Z1Z2 A178D mutant is partially unfolded.
In support, thermal denaturation experiments for Z1Z2 
A178D showed high fluorescence signal already at low tem-
peratures, suggesting solvent exposed hydrophobic residues 
because of partial unfolding. No melting temperature can be 
deducted for titin Z1Z2 A178D, in contrast to the WT protein, 
which has a melting temperature of 62°C, typical for immuno-
globulin domains (Figure IV in the Data Supplement). Small-
angle x ray scattering experiments confirmed the presence of 
unfolded parts/flexible domains in Z1Z2 A178D, as shown by 
the Kratky plot (Figure VA in the Data Supplement), whereas 
Z1Z2 WT displays a typical profile for folded structures.
The domain destabilization as a consequence of partial 
unfolding is evidenced by the formation of higher oligomers 
(≈20-mers) for the Z1Z2 A178D mutant in vitro. Size exclusion 
chromatography and Tridetector analysis revealed that in con-
trast to the monomeric Z1Z2 WT, the A178D mutant eluted in 2 
peaks, corresponding predominantly to higher molecular aggre-
gates and to a lesser extent to dimeric protein (Figure 3B and 
Table 2). Small-angle x ray scattering measurements also con-
firmed that Z1Z2 WT is monomeric, whereas Z1Z2 A178D is 
found in a higher oligomeric state (Table 2; Figure VB in the Data 
Supplement).
In conclusion, the mutation A178D leads to partial mis-
folding of bacterially expressed Z1Z2 protein fragment.
Reduced Stability of Titin Z1Z2 A178D as a Consequence 
of the Partial Misfolding
When performing denaturing gel electrophoresis, a degra-
dation product was observed exclusively for Z1Z2 A178D 
preparations (arrowhead in Figure 4A), and on thermoly-
sin treatment, only Z1Z2 A178D showed rapid degradation, 
whereas Z1Z2 WT was resistant to the protease treatment 
(Figure 4B). In addition, Z1Z2 A178D showed reduced sta-
bility when expressed in neonatal rat cardiomyocytes and 
COS-1 cells (Figure 4C; Figure VI in the Data Supplement), 
suggesting that the mutation destabilizes Z1Z2 also in a physi-
ological, cellular environment. However, formation of large 
aggregates was not observed in transfected cells expressing 
Z1Z2 A178D (Figure 4D; Figure VII in the Data Supplement).
Impaired Binding to Telethonin
Localization of transfected Z1Z2 was not altered in the 
presence of the A178D mutation (Figure 4D). To assess the 
consequences of the mutation on binding telethonin, semiquan-
titative GST pulldown assays were performed with titin Z1Z2 
and telethonin coexpressed in mammalian cells. Z1Z2 A178D 
showed impaired binding to 2 telethonin constructs (Fig-
ure 5A and 5B). The interaction between titin and telethonin 
was further quantified in Förster Resonance Energy Transfer 
experiments, where close proximity of proteins in a complex 
allows energy transfer from cyan fluorescent protein to yellow 
Figure 3. A, Circular dichroism (CD) spectroscopy of purified titin 
Z1Z2 fragments (WT solid line and A178D dashed line). B, Size 
exclusion chromatography for titin Z1Z2 fragments (WT solid line 
and A178D dashed line). Z1Z2 WT elutes as monomeric protein 
($), whereas peaks corresponding to dimer (*) and higher molecu-
lar aggregates (#) are observed for Z1Z2 A178D.
Table 2.  Biophysical Characterization of Recombinant Z1Z2 
WT and A178D Protein Fragments
 Titin Z1Z2 WT Titin Z1Z2 A178D
Calculated molecular weight, kDa 22.7 22.8
Size exclusion chromatography
  Retention time, mL 15.7
9.9 (1st peak)
14.4 (2nd peak)
Static light scattering
  Molecular weight, kDa 21±2
452±45 (1st peak)
45±4 (2nd peak)
Small-angle x ray scattering
  V
p
, excluded volume of the 
hydrated particle, nm3
40±5 305±20
  R
g
, radius of gyration, nm 3.10±0.05 6.8±0.1
  D
max
, maximum particle size, nm 10.5±0.5 25.0±1.0
  Normalized Kratky plot Folded
Partly unfolded/
flexible domains
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fluorescent protein between 2 fusion protein constructs.31 By 
introducing the A178D mutation into a Z1Zr3-cyan fluores-
cent protein construct, Förster Resonance Energy Transfer 
efficiency to telethonin-yellow fluorescent protein was almost 
abolished (Figure 5C and 5D), validating and quantifying the 
observation that A178D impairs binding to telethonin in the 
cellular context.
Taken together, our functional data suggest that the A178D 
mutant may affect protein folding and stability and impairs 
binding to telethonin, thus, supporting its pathogenic potential.
Figure 4. Destabilization of the titin Z1Z2 fragment in the presence of the A178D mutation. A, Denaturing gel-electrophoresis of purified titin 
Z1Z2 fragments (WT and A178D) expressed in Escherichia coli. The WT fragment is detected as a single band of 23 kDa (arrow). Only for 
Z1Z2 A178D, a degradation product (arrowhead) is observed. The position of marker proteins and their size (in kD) is indicated. B, Titin Z1Z2 
protein fragments (left, WT; right, A178D) were incubated with protease thermolysin for the length indicated. Control: titin Z1Z2 protein sam-
ple without thermolysin. A stable degradation fragment of ≈15 kDa is observed for the mutant titin Z1Z2. The position of marker proteins and 
their size (in kD) is indicated. C, Decreased stability of titin Z1Z2 A178D in neonatal rat cardiomyocytes (NRC). NRC were infected in dupli-
cates with adenoviral particles for hemagglutinin (HA)-tagged titin Z1Z2 (WT or A178D, MOI 5). Infection with parental empty vector (GFP) 
and noninfected cells (NI) served as controls. Steady-state titin fragment protein amount was assayed by Western blotting for the HA tag. 
Probing for humanized Renilla reniformis green fluorescent protein (hrGFP) served as infection control, and probing for endogenous GAPDH 
served as loading control. Despite equal infection rates (for confirmatory control experiments see Figure VIA in the Data Supplement), less 
titin A178D protein fragment was detected, indicating reduced stability in NRC. D, Localization of titin Z1Z2 in NRC. Cells were transfected 
with constructs coding for HA-tagged titin Z1Z2 WT (top, first row) or titin Z1Z2 A178D (bottom, first row) mutant protein fragment and coun-
terstained for endogenous titin with T12 antibody (middle row, Z-disk proximal epitope, but not recognizing the transfected titin Z1Z2 protein 
fragment). Merged images are shown in the third row; HA, in red; endogenous titin, in green. Scale bar represents 10 μm.
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Discussion
In this study, we present a 3-generation family with mul-
tiple individuals affected by cardiomyopathy with features 
of LVNC, systolic impairment, and an autosomal dominant 
inheritance pattern. Of note, the affected family members 
show a consistent phenotype with prominent hypertrabecula-
tion as the main abnormality in the majority; this is relatively 
unusual because it is more typical to see LVNC in individual 
members of families with other forms of cardiomyopathy.
We used a combination of WGS in 2 affected individuals 
and linkage analysis in 13 family members; this approach iden-
tified only 2 rare candidate variants across the whole genome 
that segregated with the autosomal dominant cardiomyopa-
thy. Because one of the identified genes (PDP2) is barely 
expressed in the heart, and the variant appears in implausible 
high numbers in the ExAC database, it is extremely unlikely to 
be disease causative. In contrast, titin, the gene affected by the 
other missense variant (TTN p.A178D), has crucial functions 
in the heart and is a known disease gene for cardiomyopa-
thies (see below). Despite the fact that the family is too small 
for traditional genome-wide linkage analysis to identify the 
genetic cause of the disease (the logarithm of the odds score 
of 2.1, ie, odds ratio 1:125, is well below the threshold of 
3.0, ie, odds ratio 1:1000), interrogation of the entire genome 
adds substantial weight to a likely causative role of the titin 
missense mutation for disease: no other plausible mutations, 
including larger genomic reorganizations (copy number vari-
ants), were detected in any other genes in the linkage regions, 
and the remainder of the genome is excluded by negative loga-
rithm of the odds scores.
Titin has been implicated in cardiac and skeletal muscle disease, 
occasionally involving a combination of both. Mutations in this gene 
have been described in various forms of cardiomyopathy, such as 
DCM, arrhythmogenic right ventricular cardiomyopathy, hypertro-
phic cardiomyopathy, and restrictive cardiomyopathy (reviewed in 
Chauveau et al27). Truncating variants in titin (TTNtv) are the most 
Figure 5. Functional implications of the titin Z1Z2 A178D mutation. A, Semiquantitative Glutathione S-transferase (GST) pulldown assays 
using telethonin fragments fused to GST (left aa 1–90, right full length) and titin Z1Z2 fragments (WT and A178D as indicated) as GFP fusions 
expressed in COS-1 cells. Bound titin-GFP fragments are detected by Western blotting (top row); input lysate controls are shown in the second 
row. Pulled down GST-telethonin fragments are shown in row three, as well as lysate controls (bottom row). B, Quantification of GST pulldown 
experiments from panel A visualizes reduced binding of titin Z1Z2 to telethonin in the presence of the A178D mutation; values are expressed as 
bound protein relative to lysate, with the first WT experiment set to 100% (n=2 per group, values expressed as mean with standard deviation for 
error bars; one representative experiment of 3 independent ones is shown). Because of the semiquantitative nature of the experiments, no sta-
tistical test was performed. C, Förster Resonance Energy Transfer (FRET) experiments using COS-1 cells cotransfected with telethonin (aa 1–90) 
fused to yellow fluorescent protein (YFP; first row) and titin Z1Zr3 fused to cyan fluorescent protein (CFP; second row). Images pre and post 
bleach are shown. FRET ratios are shown in the third row. Insets show magnification of indicated area. Scale bar represents 10 μm. D, Quanti-
fication of FRET efficiency for titin Z1Zr3 WT/A178D and telethonin pairs. The A178D mutation reduces the FRET efficiency from ≈0.15 to 0.01, 
indicating a dramatic loss of binding ability (WT n=20 and A178D n=26 cells; *P<0.0001 unpaired Student’s t test).
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frequent genetic finding in idiopathic DCM, being present in 15% 
to 25% of the cases,32 and are also frequent in peripartum cardio-
myopathy (15%).33 However, penetrance seems to be low because 
TTNtv are also found in ≈1% of normal populations, and hence, 
the large majority of carriers do not manifest with disease.34 More 
recent work35 showed that DCM causing TTNtv are enriched in the 
sarcomeric A-band region, whereas TTNtv found in control cohorts 
tend to spare the A-band region and are in exons, with low usage 
in cardiac transcripts. An internal promotor in titin rescuing TTNtv 
N-terminally of the A-band region may explain this phenomenon.36
Titin missense mutations have been identified in DCM and 
hypertrophic cardiomyopathy cohorts.4,37,38 A causative role for 
TTN p. W976R in DCM is well supported by cosegregation within 
a large family and functional data.39,40 However, generally, titin mis-
sense mutations are challenging to interpret because rare benign 
variants are common in normal population cohorts. In the ExAC 
database, more than a third of the individuals carry a rare mis-
sense variant in titin (21 939 missense variants with <0.01% allelic 
frequency in 58 687 exomes), and although a proportion of these 
may represent recessive pathogenic alleles,27 only a small fraction 
will be disease-causing with dominant inheritance. Hence, clinical 
practitioners require cosegregation information to assign causality 
because bioinformatic prediction tools can only give probabilistic 
data.4,37 As we document here, interrogation of the entire genome 
combined with linkage analysis can help to narrow down lists of 
potential causative variants, even in small families.
Our finding of TTN p.A178D in a family with features of 
LVNC expands the spectrum of titinopathies: to our knowl-
edge, this is the first report of a titin missense mutation impli-
cated in cardiomyopathy with predominant features of LVNC 
and one of the first titin missense mutations supported by 
robust genome-wide genetics and detailed functional data. The 
latter suggests a likely pathogenic role of titin A178D by (1) 
evidence of protein degradation, partial unfolding, and domain 
destabilization in vitro, (2) protein destabilization in 2 cellular 
systems, and (3) altered binding properties to the ligand tele-
thonin. Although extrapolations from such in vitro experiments 
on isolated domains to the full-length giant protein are not 
without uncertainty, such parameters will be useful comple-
ments in the future studies of other TTN missense variants. It 
is currently unclear how this particular mutation leads to this 
distinct phenotype, and more insight into the biology of Z-disk 
titin is needed to understand the underlying disease pathways. 
This will be addressed with the help of model organisms36,41 or 
patient-derived induced pluripotent stem cell–derived car-
diomyocytes,40 focussing on the titin–telethonin complex29 and 
its downstream signaling targets42 in future work.
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CLINICAL PERSPECTIVE
High throughput next-generation sequencing techniques have made whole genome sequencing accessible and are increasingly 
applied in clinical practice. However, the abundance of variation in the human genomes makes the identification of a disease-
causing mutation on a background of benign rare variants challenging. To illustrate, more than one third of individuals in normal 
population cohorts carry a rare missense variant in the giant protein titin (coded by the gene TTN), but only a small fraction of 
these will be disease-causing with dominant inheritance. Hence, titin missense variants are currently often ignored or left uninter-
preted when found in cardiomyopathy patients. Here we combine whole genome sequencing with linkage analysis in a 3-genera-
tion family affected by cardiomyopathy with features of autosomal dominant left ventricular noncompaction cardiomyopathy. 
A missense mutation in titin (TTN p. A178D) is the only plausible disease-causing variant that segregates with disease among 
affected individuals of the family, with interrogation of the entire genome excluding other potential causes. Functional studies on 
this missense mutation demonstrate domain misfolding and destabilization, resulting in paired binding to the ligand telethonin/t-
cap and, hence, supporting its highly likely causative role. Our report expands the spectrum of titin’s roles in cardiomyopathies 
and furthermore highlights that rare titin missense variants should be considered to be relevant for cardiomyopathies and can be 
identified by combining whole genome sequencing with linkage analysis in medium-sized cardiomyopathy families.
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